Reardon Andrew sold LGND
October 2, 2026 · Form 4 insider transaction
Reardon Andrew sold 17 shares of Ligand Pharmaceuticals Incorporated at $307.74 per share, a transaction worth $5.2K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Disposed (sell-side)
Shares
17
Price
$307.74
Total value
$5.2K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateOctober 2, 2026
Filing dateOctober 6, 2026
Shares owned after31,854
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.